Navigation Links
Oridion Expands its OEM Partnerships - New Agreement with Spacelabs Healthcare
Date:8/26/2008

ng statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others, our ability to maintain profits, the market demands for our Capnography products, our ability to focus our team on the Capnography business, changes in general economic and business conditions, inability to maintain market acceptance to the Company's products, inability to timely develop and introduce new technologies, products and applications, rapid changes in the market for the Company's products, loss of market share and pressure on prices resulting from competition, introduction of competing products by other companies, inability to manage growth and expansion, loss of key OEM partners, inability to attract and retain qualified personnel, inability to protect the Company's proprietary technology.

Furthermore, this press release does not constitute an offer to sell or a solicitation of an offer to buy any securities. The Company's shares issued have not been, and will not be, registered under the US Securities Act of 1933, as amended (the "Securities Act"), or under any of the relevant Securities Laws of any state of the United States. The Company's shares may not be offered, sold or delivered, directly or indirectly, to, or for, the account of any US person (as defined in regulation S under the Securities Act) in or into the United States, or by use of the US mail, or by any means or instrumentality of United States interstate commerce, absent registration, or an exemption from registration under the Securities Act.

For further Oridion information please contact:

Alan Adler, Chairman and Chief Executive Officer

Walter Tabachnik, Chief Financial Officer

Elena Gerberg, Investor Relations

e-mail: '/>"/>

SOURCE Oridion Systems Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oridion Wins 2008 Manufacturers Partnership Award From Independent Medical Distributors Association
2. Oridion Launches its Fully Integrated Remote Monitoring System and SARA Software for Improved Patient Safety
3. Hoya Vision Care Expands in Czech Republic
4. MicuRx Pharmaceuticals Selects Next-Generation Antibiotic Candidate Targeting MRSA and Expands Operation in China
5. GenVault Expands Scientific Advisory Board
6. NeoStem Expands Adult Stem Cell Collection Network, Gains Footprint in Key Los Angeles Market and Initiates Waitlist
7. Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board
8. Brinks Hofer Gilson & Lione Expands to High-Tech Raleigh/Durham Area; Adds Accomplished Patent Attorneys to Its New Office
9. SAFC Supply Solutions Expands Halal Offer in Flavors & Fragrances Product Line
10. PAREXEL Expands Global Clinical Logistics Capabilities
11. BioXcel Expands Its Capability in Business Analytics Support Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... has observed tiny quantum vortices in cold droplets of ... Science that the exotic vortices arrange themselves as ... first time that the quantum vortices, which have already ... as superfluid helium, have been detected in nanodroplets. "The ... of the University of Southern California, one of the ...
(Date:8/21/2014)... , Aug. 21, 2014 Telomere Biosciences, ... their Nutraceutical "TELO-20 for Dogs" with Telomerase ... supplement in the world for dogs. Telomeres are ... chromosome in the body. A wealth of ground-breaking ... in Telomere Science and Aging, including Nobel laureates, ...
(Date:8/21/2014)... YORK , Aug. 21, 2014 ... congratulates Immune Pharmaceuticals Inc., a biotechnology company, on ... Market.  Immune previously traded on OTCQX®, the best ... by OTC Markets Group. Logo - ... Pharmaceuticals on the successful execution of its growth ...
(Date:8/21/2014)... Ontotext S4 , The Self ... . Now the same enterprise hardened text mining, ... unstructured data is available to start-ups and mid-size businesses ... Organizations that do not have resources to evaluate and ... S4 since there is no need for on premise ...
Breaking Biology Technology:Scientists observe quantum vortices in cold helium droplets 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4
... Shionogi-ViiV Healthcare, LLC announced today that the first ... designed to support a new fixed-dose combination (FDC) ... investigational regimen, known as 572-Trii, will combine the ... combination nucleoside reverse transcriptase inhibitor (NRTI) Kivexa®/Epzicom® (ABC/3TC). ...
... TRIANGLE PARK, N.C., Feb. 2, 2011 The day ... off the shelf for use in life-saving vascular surgeries ... published in the current issue of the journal, ... vascular grafts (TEVGs) that are immediately-available at the time ...
... Inc. (Nasdaq: SGMO ) today reported fourth quarter ... For the fourth quarter ended December 31, 2010, Sangamo ... per share, compared to a net loss of $2.4  million, ... As of December 31, 2010, the company had cash, cash ...
Cached Biology Technology:Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 2Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 3Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 4Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 5Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 6Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 7Bioengineered veins offer new hope on horizon for patients lacking healthy veins for coronary bypass surgery or dialysis 2Bioengineered veins offer new hope on horizon for patients lacking healthy veins for coronary bypass surgery or dialysis 3Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 2Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 3Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 4Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 5Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 6Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 7
(Date:8/21/2014)... team has successfully replicated one of the crucial steps ... by sunlight which could manufacture hydrogen as a fuel. ... is an exciting prospect to use them to create ... Kastoori Hingorani, from the ARC Centre of Excellence for ... , Hydrogen offers potential as a zero-carbon replacement for ...
(Date:8/20/2014)... Cancer Institute (HCI) at the University of Utah have ... encodes BCR-ABL, the unregulated enzyme driving the blood cancer ... Society, nearly 6,000 new cases of CML will be ... tyrosine kinase inhibitors (TKIs), target BCR-ABL and are effective ... but control it in a way that allows patients ...
(Date:8/20/2014)... population-based screening outcomes of approximately 3 million infants, a ... at the University of Massachusetts Medical School, have shown ... be successfully implemented across public health newborn screening programs. ... Aug. 20 issue of the Journal of the ... rate of SCID in newborns is higher than previously ...
Breaking Biology News(10 mins):Water and sunlight the formula for sustainable fuel 2Blueprint for next generation of chronic myeloid leukemia treatment 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3
... the Faculty of Veterinary Medicine at Universitat Autnoma ... Research in Agricultural Genomics (CRAG), the Centre for ... for Agrarian Technology and Research in Madrid and ... the first partial genome sequencing of an Iberian ...
... The debate surrounding carbon capture and storage intensifies as ... Berkeley National Laboratory (Berkeley Lab) examine the capacity for ... in the new journal Greenhouse Gases: Science & ... the conclusions drawn in an earlier study by Ehlig-Economides ...
... biochemistry is how proteins recognize "correct" interaction partners in ... critical to know than in the brain, where interactions ... A team of biologists at the Salk Institute for ... regulates availability of a brain channel that modulates neuronal ...
Cached Biology News:First partial sequencing of an Iberian pig 2Carbon capture and storage: Carbon dioxide pressure dissipates in underground reservoirs 2Salk scientists crack molecular code regulating neuronal excitability 2Salk scientists crack molecular code regulating neuronal excitability 3
...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
... work area that will help protect your ... irradiate the work area prior to use, ... be amplified. Containment features reduce the chance ... acrylic windows for a clear view, an ...
... Have you bought a Perkin Elmer UltraVIEW system ... the Andor iXon and iQ software? No problem. ... upgrade. You keep your existing microscope, lasers, Sutter ... customise it to work with our precision controller ...
Biology Products: